- 3 hrs ago Daily Horoscope, 24 May 2022: Check Today's Horoscope Predictions For All Zodiac Signs
- 18 hrs ago What Are Empty Calories? Major Sources, Disadvantages And How To Replace Them
- 19 hrs ago Omicron Subvariants BA.4 And BA.5 In India: What You Need To Know
- 19 hrs ago First Death Of A Child Reported In Mexico Due To Mysterious Severe Hepatitis: Things To Know
- News Quad’s scope has become extensive, its form effective: PM Modi
- Movies Sarkaru Vaari Paata Day 12 Box Office Collection: Mahesh Babu's Film Slows Down At The Box Office
- Sports Racing Along The Singalong Track in Chennai
- Travel GlampEco - Glamping At India's First Geodesic Dome Stay
- Finance Motilal Oswal Suggests Buy This Stock For 25% Potential Gains, Declared Final Dividend Of Rs 6.25
- Education NABARD AM Prelims Mains 2021 Cut Off Marks, Check NABARD Assistant Manager RDBS Rajbhasha Cut Off Details Here
- Automobiles KTM RC 390 Launched At Rs 3.14 Lakhs
- Technology Vivo T2 5G Launch Postponed; Check New Launch Date, Features & Expected Pricing
A COVID-19 vaccine designed to be taken orally not only protects against the disease, but also decreases the airborne spread of the SARS-CoV-2 virus to other close contacts, according to a study conducted on animals.
The research, published in the journal Science Translational Medicine, demonstrates the potential of the vaccine to work through the mucosal tissue to neutralise SARS-CoV-2, limiting infections and the spread of active viruses in airborne particles.
"Considering most of the world is under-immunised - and this is especially true of children - the possibility that a vaccinated person with a breakthrough infection can spread COVID to unimmunised family or community members poses a public health risk," said Stephanie N Langel from Duke University Medical Center in the US.
"There would be a substantial benefit to developing vaccines that not only protect against disease, but also reduce transmission to unvaccinated people," Langel said in a statement.
The researchers - including teams from the US vaccine developer, Vaxart, and clinical research non-profit, Lovelace Biomedical Research Institute - tested the vaccine that uses an adenovirus as a vector to express the spike protein of the virus.
The spike protein is used by SARS-CoV-2 to enter and infect the human cells. The human vaccine is designed to be taken as a pill, they said. In studies using hamsters, the vaccine elicited a robust antibody response in blood and the lungs.
When the animals were exposed to the SARS-CoV-2 virus at high levels, prompting breakthrough infections, they were less symptomatic than non-vaccinated hamsters, and had lower amounts of infectious virus in the nose and lungs.
Because of this, they did not shed as much virus through normal airborne exposures, according to the researchers.
Unlike vaccines that are injected into the muscle, they said, mucosal immunisations increase the production of immunoglobulin A (IgA) - the immune system's first line of defence against pathogens - in the nose and lungs.
These mucosal ports of entry are then protected, making it less likely that those who are vaccinated will transmit the infectious virus during a sneeze or cough, the researchers said.
"Our data demonstrate that mucosal immunisation is a viable strategy to decrease the spread of COVID through airborne transmission," Langel said.
The researchers noted that the study focused on the original SARS-CoV-2 virus, and new studies will be designed to test the vaccine against Omicron variants.
- healthCovid-19 Vaccination: SC Order States That 'No One Can Be Forced To Get Vaccinated:' 7 Main Points
- wellnessHow To Safely Reuse N95 Masks: Expert Explains
- disorders cureCovid Omicron XE: Symptoms And Everything You Need To Know About The Combined Variant
- wellnessNew COVID Mutant XE Omicron Variant Could Be Most Transmissible Yet: WHO
- disorders cureHybrid COVID Variant Reported In India: Know The Symptoms Here
- wellnessCOVID-19: DGCI Grants Restricted Emergency-Use Nod To Corbevax Vaccine For 12-18 Age Group
- wellnessDecision On COVID Vaccination For 5-15 Age Group To Be Taken As Per Experts' Recommendation: Health Minister
- wellnessDecision On COVID-19 Vaccine Precaution Dose For All Adults Will Be Based On Scientific Need: Govt
- healthIndia's First Homegrown Mrna Covid-19 Vaccine Currently Under Final Clinical Trial Stages: Govt
- disorders cureIndia's 1st COVID Nasal Spray FabiSpray For Treating Adult COVID-19 Patients Launched: Read Details
- wellnessExpert Article: Does COVID-19 Vaccine Provide Effective Protection Against Omicron?
- wellnessCOVID Vaccine 4th Dose Shows Limited Results With Omicron, Says Study In Israel